S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

BiondVax Pharmaceuticals (BVXV) Stock Forecast, Price & News

0.00 (0.00%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
24,572 shs
Average Volume
879,968 shs
Market Capitalization
$14.76 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BiondVax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BiondVax Pharmaceuticals logo

About BiondVax Pharmaceuticals

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.


See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$0.66 per share


Net Income
$-12.85 million
Pretax Margin




Free Float
Market Cap
$14.76 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.53 out of 5 stars

Medical Sector

1015th out of 1,424 stocks

Biological Products, Except Diagnostic Industry

156th out of 209 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

BiondVax Pharmaceuticals (NASDAQ:BVXV) Frequently Asked Questions

Is BiondVax Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BiondVax Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BiondVax Pharmaceuticals stock.
View analyst ratings for BiondVax Pharmaceuticals
or view top-rated stocks.

Are investors shorting BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 61,600 shares, a decline of 16.4% from the April 30th total of 73,700 shares. Based on an average daily trading volume, of 1,140,000 shares, the short-interest ratio is presently 0.1 days.
View BiondVax Pharmaceuticals' Short Interest

When is BiondVax Pharmaceuticals' next earnings date?

BiondVax Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, June 22nd 2022.
View our earnings forecast for BiondVax Pharmaceuticals

How were BiondVax Pharmaceuticals' earnings last quarter?

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) posted its earnings results on Monday, March, 28th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.18.
View BiondVax Pharmaceuticals' earnings history

What price target have analysts set for BVXV?

1 equities research analysts have issued 1 year target prices for BiondVax Pharmaceuticals' stock. Their forecasts range from $7.00 to $7.00. On average, they anticipate BiondVax Pharmaceuticals' stock price to reach $7.00 in the next year. This suggests a possible upside of 438.5% from the stock's current price.
View analysts' price targets for BiondVax Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are BiondVax Pharmaceuticals' key executives?
BiondVax Pharmaceuticals' management team includes the following people:
  • Mr. Amir Reichman M.B.A., M.Sc., CEO & Director (Age 46)
  • Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA, Chief Financial Officer (Age 52)
  • Mr. Elad Mark B.Sc., Eng., M.B.A., Chief Operating Officer (Age 40)
  • Dr. Tamar Ben-Yedidia Ph.D., Chief Scientist (Age 58)
  • Mr. Joshua E. Phillipson B.Sc., M.B.A., Director of Bus. Devel. & Investor Relations
  • Ms. Moran Ahdout Fruchter L.L.B., Chief of Staff
  • Ms. Dalit Weinstein Fischer, Head of Technical R&D
What other stocks do shareholders of BiondVax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BiondVax Pharmaceuticals investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pluristem Therapeutics (PSTI), Exelixis (EXEL), NVIDIA (NVDA), Teva Pharmaceutical Industries (TEVA), Adaptimmune Therapeutics (ADAP), AVEO Pharmaceuticals (AVEO), Anavex Life Sciences (AVXL) and Alibaba Group (BABA).

When did BiondVax Pharmaceuticals IPO?

(BVXV) raised $10 million in an IPO on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp acted as the underwriter for the IPO.

What is BiondVax Pharmaceuticals' stock symbol?

BiondVax Pharmaceuticals trades on the NASDAQ under the ticker symbol "BVXV."

How do I buy shares of BiondVax Pharmaceuticals?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BiondVax Pharmaceuticals' stock price today?

One share of BVXV stock can currently be purchased for approximately $1.30.

How much money does BiondVax Pharmaceuticals make?

BiondVax Pharmaceuticals has a market capitalization of $14.76 million. The company earns $-12.85 million in net income (profit) each year or ($0.76) on an earnings per share basis.

How many employees does BiondVax Pharmaceuticals have?

BiondVax Pharmaceuticals employs 15 workers across the globe.

What is BiondVax Pharmaceuticals' official website?

The official website for BiondVax Pharmaceuticals is www.biondvax.com.

How can I contact BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals' mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 9723029302529, via email at [email protected], or via fax at 972-8930-2531.

This page was last updated on 5/29/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.